Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04276259 · ClinicalTrials.gov registry record · Phase 4
Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses
A Phase 4 study, sponsored by Marta Peciña, MD PhD.
- Completed
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
NCT04276259: Completed Phase 4 study, sponsored by Marta Peciña, MD PhD.
NCT04276259 is a Phase 4 study that has completed, run by Marta Peciña, MD PhD. The registered enrollment target is 120 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04276259, a Phase 4 study, has completed, sponsored by Marta Peciña, MD PhD.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
Study Summary
The central goal of this application is to demonstrate the causal contribution of reward learning signals (expected values and reward prediction errors \[RPE\]) to antidepressant responses (Aim1) by experimentally manipulating expected values using transcranial magnetic stimulation (TMS) targeting the vmPFC (Aim 2) and μ-opioid striatal RPE signal using pharmacological approaches (Aim 3).
Primary Outcome
Changes in blood oxygenation level-dependent (BOLD) signal during the Antidepressant fMRI Task.
Interventions
- DRUG Oral Placebo
- DRUG Buprenorphine
- DRUG Naltrexone
- DRUG IM Placebo
- DEVICE Theta burst stimulation (TBS) of the ventromedial prefrontal cortex.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2020-10-19 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 4 |
What the finished NCT04276259 record still lists
NCT04276259 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 5 interventions - of which Oral Placebo is the first listed.
NCT04276259 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04276259 about?
NCT04276259 is a clinical study titled "Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses". The central goal of this application is to demonstrate the causal contribution of reward learning signals (expected values and reward prediction errors \[RPE\]) to antidepressant responses (Aim1) by experimentally manipulating expected values using transcranial magnetic stimulation (TMS) targeting t...
What is the current status of trial NCT04276259?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2020-10-19. Estimated completion is 2026-03-31.
What interventions are being tested in trial NCT04276259?
The interventions under investigation include: Oral Placebo (DRUG), Buprenorphine (DRUG), Naltrexone (DRUG), IM Placebo (DRUG), Theta burst stimulation (TBS) of the ventromedial prefrontal cortex. (DEVICE).
Who is sponsoring clinical trial NCT04276259?
This trial is sponsored by Marta Peciña, MD PhD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04276259's enrollment target sits among peer trials
120 673rd of 2000 higher than 1,289 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI